Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4275
Source ID: NCT00458016
Associated Drug: Mb07803
Title: Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: MB07803|DRUG: Placebo
Outcome Measures: Primary: Fasting Plasma Glucose Concentration, Change from baseline to Day 28 | Secondary: Fasting serum triglycerides and free fatty acids, fasting serum insulin., Change from baseline to Day 28
Sponsor/Collaborators: Sponsor: Ligand Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 105
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2007-03
Completion Date: 2008-03
Results First Posted:
Last Update Posted: 2011-10-03
Locations: Los Angeles, California, 90057, United States|Walnut Creek, California, 94598, United States|Miami Gardens, Florida, 33169, United States|Miami, Florida, 33169, United States|Chicago, Illinois, 60607, United States|Chicago, Illinois, 60611, United States|Indianapolis, Indiana, 46254, United States|Indianapolis, Indiana, 46260, United States|Butte, Montana, 59701, United States|Las Vegas, Nevada, 89123, United States|Charlotte, North Carolina, 28209, United States|Statesville, North Carolina, 28677, United States|Winston- Salem, North Carolina, 27103, United States|Cincinnati, Ohio, 45246, United States|Delaware, Ohio, 43015, United States|Marion, Ohio, 43302, United States|Willoughby Hills, Ohio, 44094, United States|Tulsa, Oklahoma, 74104, United States|Charleston, South Carolina, 29407, United States|Bristol, Tennessee, 37620, United States|Corpus Christi, Texas, 78404, United States|Dallas, Texas, 75231, United States|Houston, Texas, 77030, United States|San Antonio, Texas, 78229, United States|Richmond, Virginia, 23249, United States
URL: https://clinicaltrials.gov/show/NCT00458016